Literature DB >> 9111517

Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo.

J Laterra1, M Nam, E Rosen, J S Rao, K Lamszus, I D Goldberg, P Johnston.   

Abstract

Scatter factor (SF), also known as hepatocyte growth factor, is angiogenic in systemic tissue, and SF titers correlate with the malignancy and metastatic phenotype of certain systemic cancers. Human gliomas express SF and its receptor c-met, but their role in the malignant progression of these tumors has not been defined. To examine this, 9L glioma cells that express c-met but not SF were transfected with human SF cDNA, and their behavior in vitro and in vivo was examined. SF gene expression was detected in conditioned medium of 9L-SF but not in control 9L-neo-transfected cell lines, by reverse transcriptase-PCR, immunoblot, ELISA, and scatter activity assays. Gliomas derived from 9L-SF and control 9L-neo cell lines implanted in the caudate/putamen of Fisher 344 rats (intracranially) and in the flanks of SCID/Beige mice (subcutaneously) were examined. Extracts from intracranial (i.c.) gliomas contained elevated levels of SF protein as determined by ELISA (1 to 5.5 ng SF/mg protein), whereas no SF was detected in control tumors. Reverse transcriptase-PCR of RNA from i.c. gliomas revealed that only 9L-SF gliomas expressed SF and both 9L-neo and 9L-SF gliomas expressed the c-met SF receptor. By postimplantation Day 14, 9L-SF i.c. gliomas were approximately 5-fold larger than 9L-neo control tumors (p < 0.001). Subcutaneous 9L-SF glioma growth was also greater than that in controls, although the differences were more variable. SF-producing i.c. gliomas contained elevated levels of 48-kd urokinase (3.5-fold) and 92-kd type IV collagenase (2.8-fold), both enzymes that correlate with the malignant progression of human gliomas (p < 0.001). SF-producing and control 9L cell lines did not differ in rates of proliferation, thymidine incorporation, or adhesion-independent growth in vitro. Conditioned medium from 9L-SF cells stimulated thymidine incorporation into microvessel brain endothelial cells 3- to 4-fold higher than did CM from 9L-neo controls (p < 0.001). Intracranial 9L-SF gliomas were more angiogenic than controls based on elevated peak (2.25-fold; p < 0.005) and mean (1.7-fold; p < 0.008) blood vessel densities. These results suggest that SF production by glioma cells enhances glioma malignancy in vivo, in part, by paracrine mechanisms involving glioma-associated angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9111517

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  29 in total

1.  Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line.

Authors:  S Yi; M S Tsao
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

2.  Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion.

Authors:  Mireia Náger; Maria Santacana; Deepshikha Bhardwaj; Joan Valls; Isidre Ferrer; Pere Nogués; Carles Cantí; Judit Herreros
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival.

Authors:  Qing-le Liang; Zheng-ying Mo; Ping Wang; Xiao Li; Zhi-xiang Liu; Zhang-ming Zhou
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

4.  A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

Authors:  James I Geller; John P Perentesis; Xiaowei Liu; Charles G Minard; Rachel A Kudgus; Joel M Reid; Elizabeth Fox; Susan M Blaney; Brenda J Weigel
Journal:  Pediatr Blood Cancer       Date:  2017-04-27       Impact factor: 3.167

Review 5.  Genes that regulate metastasis and angiogenesis.

Authors:  C P Webb; G F Vande Woude
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

Review 6.  Microvascular modifications in diabetic retinopathy.

Authors:  Jennifer T Durham; Ira M Herman
Journal:  Curr Diab Rep       Date:  2011-08       Impact factor: 4.810

7.  Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models.

Authors:  B Cao; Y Su; M Oskarsson; P Zhao; E J Kort; R J Fisher; L M Wang; G F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

Review 8.  Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis.

Authors:  Roger Abounader; John Laterra
Journal:  Neuro Oncol       Date:  2005-10       Impact factor: 12.300

9.  An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.

Authors:  Fadila Guessous; Ying Zhang; Charles diPierro; Lukasz Marcinkiewicz; Jann Sarkaria; David Schiff; Sean Buchanan; Roger Abounader
Journal:  Anticancer Agents Med Chem       Date:  2010-01       Impact factor: 2.505

10.  MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.

Authors:  Yunqing Li; Fadila Guessous; Ying Zhang; Charles Dipierro; Benjamin Kefas; Elizabeth Johnson; Lukasz Marcinkiewicz; Jinmai Jiang; Yanzhi Yang; Thomas D Schmittgen; Beatriz Lopes; David Schiff; Benjamin Purow; Roger Abounader
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.